Monrol Is Partnering With Telix Pharmaceuticals, Supplying Lutetium nca Lu 177 for the Manufacturing

ISTANBUL--(BUSINESS WIRE)--#MSKCC--Eczacıbaşı-Monrol Nuclear Products Co. (Monrol) has today announced that the first patient has been dosed in the ‘STARLITE 2’ Phase II study of Telix Pharmaceuticals Limited (Telix) investigational renal cancer therapy product, TLX250 (177Lu-DOTA-girentuximab), at Memorial Sloan Ke...

Related Keywords

New York ,United States ,Australia ,Memorial Sloan Kettering Cancer Center ,Japan ,Istanbul ,Turkey ,United Kingdom ,Belgium ,Melbourne ,Victoria ,Canada ,Switzerland ,Australian ,British ,Aydin Kucuk ,Darren Feldman ,Colin Hayward ,Monrol Lu ,Telix Pharmaceuticals ,Linkedin ,Drug Administration ,Monrol Nuclear Products Co ,Australian Securities Exchange ,Telix Pharmaceuticals Limited ,Australian Therapeutic Goods Administration ,Bristol Myers Squibb ,Monrol Nuclear Products ,Adrenal Cancer ,Monrol General Manager Aydin ,Chief Medical Officer ,Neuro Endocrine Tumors ,Positron Emission Tomography ,Breakthrough Therapy ,Molecularly Targeted Radiation ,Bristol Myers ,